Latest & greatest articles for breast cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer screening

201. Benefits and costs of screening and treatment for early breast cancer: development of a basic benefit package

Benefits and costs of screening and treatment for early breast cancer: development of a basic benefit package Benefits and costs of screening and treatment for early breast cancer: development of a basic benefit package Benefits and costs of screening and treatment for early breast cancer: development of a basic benefit package Kattlove H, Liberati A, Keeler E, Brook R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening and treatment strategies for early breast cancer. Type of intervention Screening and treatment. Economic study type Cost-effectiveness analysis. Study population A hypothetical health care organisation with an enrolled population of 500,000, in which 360 new cases of breast cancer would be expected

NHS Economic Evaluation Database.1995

202. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening.

UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. 7488893 1996 01 04 1996 01 04 2016 11 23 0959-8138 311 7014 1995 Nov 04 BMJ (Clinical research ed.) BMJ UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. 1189-93 To compare one view (oblique) and two view (oblique and craniocaudal) mammography in breast cancer screening. Randomised controlled trial. Nine breast screening centres (...) in England. 40,163 women aged 50-64 attending their first breast screening examination. Women were randomised to have one view mammography, two view mammography, or two view mammography in which one view was read by one reader and both views were read by another. Prevalence of cancer detected, recall rates, cost per cancer detected, and marginal cost per extra cancer detected. Two view mammography detected 24% more women with breast cancer (95% confidence interval 16% to 31%) than one view mammography

BMJ1995 Full Text: Link to full Text with Trip Pro

203. Screening and self examination for breast cancer

Screening and self examination for breast cancer Screening and self examination for breast cancer Screening and self examination for breast cancer Austoker J Authors' objectives To summarise for a primary care audience evidence about the effectiveness of breast screening by mammography and breast self examination. Searching Not stated. This is more a review of reviews: see CRD Comments field. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs (...) . Results of the review Six RCTs comparing mortality in women aged 50-74 (and with sub-group analyses for women aged 40-49) invited for screening with controls. In women aged 50-74, breast cancer mortality is reduced by 28% among those screened (95% CI not stated, but shown diagrammatically). In women aged 40-49, there was no significant reduction in mortality (95% CI for relative risk includes 1). Benefits of screening include improved prognosis and less radical treatment for cases detected early

DARE.1994

204. Screening for breast cancer in women aged 40-49 years

Screening for breast cancer in women aged 40-49 years Screening for breast cancer in women aged 40-49 years Screening for breast cancer in women aged 40-49 years Caro J J, O'Brien J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Caro J J, O'Brien J. Screening for breast cancer in women aged 40-49 years. Montreal: Conseil d'Evaluation des (...) Technologies de la Sante du Quebec (CETS). 1993 Authors' objectives To review and analyze the evidence relating to possible health benefits, adverse effects and costs of periodic mammographic screening of women aged age 40 to 49 years, in the absence of any reasons for suspicion of breast cancer. Authors' conclusions Public policy involving the lives of thousands of individuals and large resources should not normally be made in the absence of either direct evidence of benefit or at least, extremely

Health Technology Assessment (HTA) Database.1993

205. Breast cancer screening with mammography: overview of Swedish randomised trials.

Breast cancer screening with mammography: overview of Swedish randomised trials. 8096941 1993 05 11 1993 05 11 2016 11 23 0140-6736 341 8851 1993 Apr 17 Lancet (London, England) Lancet Breast cancer screening with mammography: overview of Swedish randomised trials. 973-8 Despite encouraging results from screening trials the efficacy of mammography in reducing mortality remains somewhat controversial. Five studies have been done in Sweden. This overview, based on 282,777 women followed for 5-13 (...) years in randomised trials in Malmö, Kopparberg, Ostergötland, Stockholm, and Gothenburg, reveals a 24% (95% confidence interval 13-34%) significant reduction of breast cancer mortality among those invited to mammography screening compared with those not invited. To avoid the potential risk of differential misclassification causes of death were assessed by an independent end-point committee after a blinded review of all fatal breast cancer cases. The mortality reduction was similar, irrespective

Lancet1993

206. Economic analysis of screening for breast cancer: report for Scottish Home and Health Department

Economic analysis of screening for breast cancer: report for Scottish Home and Health Department Economic analysis of screening for breast cancer: report for Scottish Home and Health Department Economic analysis of screening for breast cancer: report for Scottish Home and Health Department Clarke P R, Fraser N M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) , was not statistically significant at seven years. 7) The hypothesis was driven. 8) There were health omissions. Bibliographic details Clarke P R, Fraser N M. Economic analysis of screening for breast cancer: report for Scottish Home and Health Department. Edinburgh: Scottish Office. 1991 Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms /diagnosis; Costs and Cost Analysis; Female; Mammography /economics; Mass Screening /economics; Middle Aged; Quality of Life AccessionNumber 21995005188 Date

NHS Economic Evaluation Database.1991

207. Edinburgh trial of screening for breast cancer: mortality at seven years.

Edinburgh trial of screening for breast cancer: mortality at seven years. 1967717 1990 03 09 1990 03 09 2015 06 16 0140-6736 335 8684 1990 Feb 03 Lancet (London, England) Lancet Edinburgh trial of screening for breast cancer: mortality at seven years. 241-6 Between 1979 and 1981, 45,130 women in Edinburgh aged 45-64 were entered into a randomised trial of breast cancer screening by mammography and clinical examination. The initial attendance rate was 61% but this varied according to age (...) ):968-9 1970035 Age Factors Breast Neoplasms epidemiology mortality pathology prevention & control Carcinoma epidemiology mortality pathology prevention & control Evaluation Studies as Topic Female Follow-Up Studies Health Education Humans Mammography Mass Screening methods Middle Aged Neoplasm Staging Physical Examination Predictive Value of Tests Registries Scotland epidemiology Socioeconomic Factors Space-Time Clustering 1990 2 3 1990 2 3 0 1 1990 2 3 0 0 ppublish 1967717

Lancet1990

208. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.

Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. 3142562 1989 01 09 1989 01 09 2016 11 23 0959-8138 297 6654 1988 Oct 15 BMJ (Clinical research ed.) BMJ Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. 943-8 To determine whether mortality from breast cancer could be reduced by repeated mammographic screening. Birth year cohorts of city population separately randomised into study and control groups (...) . Screening clinic outside main hospital. Women aged over 45; 21,088 invited for screening and 21,195 in control group. Women in the study group were invited to attend for mammographic screening at intervals of 18-24 months. Five rounds of screening were completed. Breast cancer was treated according to stage at diagnosis. Mortality from breast cancer. All women were followed up and classed at end point as alive without breast cancer, alive with breast cancer, dead from breast cancer, or dead from other

BMJ1988 Full Text: Link to full Text with Trip Pro

209. Survival in breast cancer diagnosed between mammographic screening examinations.

Survival in breast cancer diagnosed between mammographic screening examinations. 2873324 1986 08 04 1986 08 04 2016 11 23 0140-6736 2 8497 1986 Jul 05 Lancet (London, England) Lancet Survival in breast cancer diagnosed between mammographic screening examinations. 27-30 In women drawn from a randomised, population-based trial of mammography screening for breast cancer the overall actuarial survival and disease-free survival for up to 7 years of observation were similar in 94 patients (...) with interval cancers and 178 control patients with cancer diagnosed independent of screening. The similarity was confirmed by multiple regression analysis. These results contradict the hypothesis that a high growth rate of the primary tumour is associated with a greater metastatic potential and do not support the concept that patients with interval cancers should receive more aggressive local or systemic treatment. Holmberg L H LH Tabar L L Adami H O HO Bergström R R eng Clinical Trial Journal Article

Lancet1986

210. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare.

Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. 2858707 1985 05 17 1985 05 17 2016 11 23 0140-6736 1 8433 1985 Apr 13 Lancet (London, England) Lancet Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare (...) . 829-32 A randomised controlled trial to investigate the efficacy of mass screening with single-view mammography in reducing mortality from breast cancer was started in Sweden in 1977. 162 981 women aged 40 years or more and living in the counties of Kopparberg and Ostergötland were enrolled in the study and divided at random into 2 groups. Each woman in the study group was offered screening every 2 or 3 years depending on age. Women in the control group were not offered screening. This report

Lancet1985

211. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981.

Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. 6144933 1984 07 06 1984 07 06 2016 11 23 0140-6736 1 8388 1984 Jun 02 Lancet (London, England) Lancet Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. 1222-4 Since 1975 four rounds of screening with modern mammography for breast cancer have been carried out among 30 000 (...) Nijmegen women born before 1940. The results up to the end of 1981 shows that the odds ratio of screened vs unscreened subjects among women who died from breast cancer compared with women who did not, was 0.48 (95% confidence interval 0.23-1.00) in all age groups. Verbeek A L AL Hendriks J H JH Holland R R Mravunac M M Sturmans F F Day N E NE eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't England Lancet 2985213R 0140-6736 AIM IM Adult Aged Breast

Lancet1984

212. Breast cancer screening and health service costs

Breast cancer screening and health service costs Breast cancer screening and health service costs Breast cancer screening and health service costs Gravelle H S, Simpson P R, Chamberlain J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Type (...) details Gravelle H S, Simpson P R, Chamberlain J. Breast cancer screening and health service costs. Journal of Health Economics 1982; 1(2): 185-207 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Breast Neoplasms /epidemiology /prevention & Costs and Cost Analysis; Female; Great Britain; Humans; Mammography /economics; Mass Screening /economics; Middle Aged; State Medicine /economics; control AccessionNumber 21995005276 Date bibliographic record published 06/08/1996 Date abstract

NHS Economic Evaluation Database.1982